SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-017819
Filing Date
2023-05-04
Accepted
2023-05-04 16:02:25
Documents
77
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q apls-20230331.htm   iXBRL 10-Q 2314334
2 EX-31.1 apls-ex31_1.htm EX-31 21525
3 EX-31.2 apls-ex31_2.htm EX-31 20748
4 EX-32.1 apls-ex32_1.htm EX-32 11724
5 EX-32.2 apls-ex32_2.htm EX-32 11896
  Complete submission text file 0000950170-23-017819.txt   9268711

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT apls-20230331_lab.xml EX-101.LAB 511527
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT apls-20230331_pre.xml EX-101.PRE 365470
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT apls-20230331_cal.xml EX-101.CAL 64003
9 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT apls-20230331.xsd EX-101.SCH 75360
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT apls-20230331_def.xml EX-101.DEF 212264
71 EXTRACTED XBRL INSTANCE DOCUMENT apls-20230331_htm.xml XML 1737609
Mailing Address 100 FIFTH AVENUE WALTHAM MA 02451
Business Address 100 FIFTH AVENUE WALTHAM MA 02451 617-977-5700
Apellis Pharmaceuticals, Inc. (Filer) CIK: 0001492422 (see all company filings)

IRS No.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38276 | Film No.: 23888503
SIC: 2834 Pharmaceutical Preparations